New genetic syndrome bridges the gap between neurodevelopmental and neurodegenerative disorders

In a landmark discovery, researchers from the University of Antioquia have identified a new genetic syndrome that bridges the gap between neurodevelopmental disorders and neurodegenerative diseases.

Hutchmed’s licensing deal, worth up to $227M; Tyra’s $200 PIPE

Plus, news about Anbogen Therapeutics and Vera Therapeutics: Hutchmed inks deal of up to $227.5M: The company is licensing two drugs to Immagene Biopharmaceuticals: IMG-007,

February 3, 2024

NS Pharma asset gains FDA rare paediatric disease status

NS Pharma’s NS-089/NCNP-02 (brogidirsen) is intended for patients with Duchenne muscular dystrophy. Credit: Jose Luis Calvo via Shutterstock.com. The US Food and Drug Administration (FDA) has

July 10, 2023

Data Insights – Pharmaceutical Technology

By Company Name No Filter Selected Bristol-Myers Squibb (266) Pfizer (262) AstraZeneca (232) Merck (208) Novartis (189) AbbVie (174) F. Hoffmann-La Roche (152) BeiGene (151)

June 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.